- Home
- CRT vs OKYO Comparison
CRT vs OKYO Comparison
Compare CRT & OKYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CRT | OKYO |
|---|---|---|
| Founded | 1991 | 2007 |
| Country | United States | United Kingdom |
| Employees | 2 | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.5M | 71.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | CRT | OKYO |
|---|---|---|
| Price | $12.07 | $1.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.33 |
| AVG Volume (30 Days) | 31.8K | ★ 67.2K |
| Earning Date | 11-13-2026 | 07-20-2026 |
| Dividend Yield | ★ 5.43% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.55 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.07 | $1.26 |
| 52 Week High | $13.15 | $3.20 |
Technical Indicators
Market Signals| Indicator | CRT | OKYO |
|---|---|---|
| Relative Strength Index (RSI) | 56.03 | 47.00 |
| Support Level | $10.18 | $1.29 |
| Resistance Level | $13.05 | $1.72 |
| Average True Range (ATR) | 0.52 | 0.08 |
| MACD | -0.09 | 0.01 |
| Stochastic Oscillator | 48.56 | 55.60 |
Price Performance
Historical ComparisonAbout CRT Cross Timbers Royalty Trust
Cross Timbers Royalty Trust is a United States-based trust. The net profits interests are derived from producing royalty, overriding royalty interests, and working interest properties. The underlying properties of the trust include producing properties in Texas, Oklahoma, and New Mexico.
About OKYO OKYO Pharma Limited
OKYO Pharma Ltd is a clinical-stage ophthalmology company focused on developing differentiated therapies for corneal and anterior segment diseases. It is advancing a pipeline designed to improve outcomes for patients suffering from debilitating ocular diseases that impact vision and ocular comfort. The company's main program, urcosimod, is being developed as a potential treatment for neuropathic corneal pain. Additionally, its development pipeline includes an exploratory candidate, OK-201, a non-opioid analgesic drug candidate, as a potential drug to treat acute and chronic ocular pain. The company has only one operating segment: the research and development of biotechnological and pharmaceutical products.